Aldeyra Therapeutics (ALDX)
(Delayed Data from NSDQ)
$4.69 USD
-0.02 (-0.42%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $4.70 +0.01 (0.21%) 4:58 PM ET
4-Sell of 5 4
D Value C Growth F Momentum D VGM
Price, Consensus and EPS Surprise
ALDX 4.69 -0.02(-0.42%)
Will ALDX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ALDX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ALDX
Is Aldeyra Therapeutics (ALDX) Stock Outpacing Its Medical Peers This Year?
Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?
ALDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
Here's Why You Should Invest in Aldeyra (ALDX) Stock Now
Other News for ALDX
Analysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (XERS), Aldeyra Therapeutics (ALDX) and Immunic (IMUX)
Buy Recommendation for Aldeyra Therapeutics Amid Positive Phase 3 Results for Reproxalap
Aldeyra Therapeutics: A Buy Rating on Strong Clinical Progress and Market Potential
Aldeyra climbs after late-stage success for dry eye disease therapy
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap